These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37979306)
1. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306 [TBL] [Abstract][Full Text] [Related]
2. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859 [TBL] [Abstract][Full Text] [Related]
3. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609 [TBL] [Abstract][Full Text] [Related]
4. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531 [TBL] [Abstract][Full Text] [Related]
5. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945 [TBL] [Abstract][Full Text] [Related]
6. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513 [TBL] [Abstract][Full Text] [Related]
7. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report. Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431 [TBL] [Abstract][Full Text] [Related]
8. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904 [TBL] [Abstract][Full Text] [Related]
9. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P Front Immunol; 2022; 13():809971. PubMed ID: 35185898 [TBL] [Abstract][Full Text] [Related]
10. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
11. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
12. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842 [TBL] [Abstract][Full Text] [Related]
14. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794 [TBL] [Abstract][Full Text] [Related]
15. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082 [TBL] [Abstract][Full Text] [Related]
16. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer. Veen T; Kanani A; Lea D; Søreide K Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319 [TBL] [Abstract][Full Text] [Related]
18. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992 [TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]